NYMOX PHARM CORP (NYMXF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 21, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2024, filed Jun 3, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NYMXF SEC filings page.
This page shows NYMOX PHARM CORP (NYMXF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The filings portray a cash-consuming, financing-dependent business whose liabilities now vastly exceed its shrinking asset base.
In FY2024, operating cash flow of-$2.6M was nearly matched by financing cash flow of$2.6M , so reported operations did not fund reported cash needs. The same pairing appeared in FY2022, when operating cash flow was-$5.2M against$5.8M of financing inflow, indicating a recurring funding pattern rather than a one-year event.
FY2024 liabilities of
The current ratio fell from 2.0x in FY2020 to 0.1x in FY2024, so current assets no longer cover current liabilities. Meanwhile, valid revenue is available only for FY2020 at
Financial Health Signals
NYMOX PHARM CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2024.
Cash & Balance Sheet
NYMOX PHARM CORP recorded an outflow of $717K in free cash flow in Q4 2024, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
NYMOX PHARM CORP held $74K in cash as of Q4 2024; no long-term debt figure is on record for that period.
Not reported for Q4 2024.
Margins & Returns
None of these metrics is reported for Q4 2024.
Capital Allocation
NYMOX PHARM CORP reported no capital expenditure in Q4 2024. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Not reported for Q4 2024.
Not reported for Q4 2024.
NYMXF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2420-F | Q3'246-K | Q4'2320-F | Q3'236-K | Q2'236-K | Q1'236-K | Q4'2220-F | Q3'226-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0n/m | N/A | $0n/m | $0n/m | $0n/m | N/A | $0n/m |
| Cost of Revenue | N/A | $0n/m | N/A | $0n/m | $0n/m | $0n/m | N/A | $0n/m |
| Gross Profit | N/A | $0n/m | N/A | $0n/m | $0n/m | $0n/m | N/A | $0n/m |
| R&D Expenses | N/A | $511K-22.7% | N/A | $661K-25.9% | $594K-26.7% | $720K-83.4% | N/A | $892K-51.5% |
| Interest Expense | N/A | $63K+186.4% | N/A | $22K+120.0% | $10K+900.0% | $2K-33.3% | N/A | $10K |
| Net Income | N/A | N/A | N/A | N/A | N/A | -$1.4Mn/m | N/A | N/A |
| EPS (Basic) | N/A | N/A | N/A | N/A | N/A | N/A | -$0.01n/m | -$0.02n/m |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$0.02n/m |
Not reported in any period shown, so not listed: SG&A Expenses, Operating Income, EBITDA, Income Tax, Diluted Shares (Avg).
NYMXF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2420-F | Q3'246-K | Q4'2320-F | Q3'236-K | Q2'236-K | Q1'236-K | Q4'2220-F | Q3'226-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $654K+4.3% | $624K-6.7% | $627K-61.4% | $669K-78.7% | $271K-93.9% | $575K-53.6% | $1.6M+12.6% | $3.1M-18.4% |
| Current Assets | $653K+4.5% | $623K-4.7% | $625K-57.1% | $654K-77.5% | $214K-94.9% | $461K-48.2% | $1.5M+40.5% | $2.9M-14.2% |
| Cash & Equivalents | $74K+5.7% | $41K-46.1% | $70K-95.0% | $76K-97.2% | $132K-96.8% | $351K-47.8% | $1.4M+69.0% | $2.7M-13.9% |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $34K0.0% |
| Total Liabilities | $7.4M+95.5% | $6.9M+169.2% | $3.8M+80.4% | $2.6M+8.6% | $3.1M+40.4% | $2.4M-9.7% | $2.1M+8.1% | $2.4M+4.4% |
| Current Liabilities | $7.4M+95.5% | $6.9M+169.2% | $3.8M+80.4% | $2.6M+9.1% | $3.1M+43.7% | $2.4M-5.8% | $2.1M+18.0% | $2.4M+29.3% |
| Non-Current Liabilities | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $11K-97.5% |
| Total Equity | -$6.8Mn/m | -$6.3Mn/m | -$3.2Mn/m | -$1.9M-346.1% | -$2.9M-228.9% | -$1.8Mn/m | -$482Kn/m | $773K-51.2% |
| Retained Earnings | -$212.5Mn/m | N/A | -$208.0Mn/m | N/A | N/A | N/A | -$199.1Mn/m | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.
NYMXF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2420-F | Q3'246-K | Q4'2320-F | Q3'236-K | Q2'236-K | Q1'236-K | Q4'2220-F | Q3'226-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$717Kn/m | N/A | -$897Kn/m | -$1.3Mn/m | -$909K-158.4% | -$988Kn/m | -$1.2Mn/m | -$1.3Mn/m |
| Capital Expenditures | $0n/m | N/A | $0n/m | $0n/m | $0n/m | $3Kn/m | $0-100.0% | $0n/m |
| Free Cash Flow | -$717Kn/m | N/A | -$897Kn/m | -$1.3Mn/m | -$909K-158.4% | -$991Kn/m | -$1.2Mn/m | -$1.3Mn/m |
| Investing Cash Flow | $0n/m | N/A | $0n/m | $0n/m | $0n/m | -$3Kn/m | $0n/m | $0n/m |
| Financing Cash Flow | $750K-15.8% | N/A | $891Kn/m | $1.2Mn/m | $690K-62.5% | -$61K-101.5% | -$52Kn/m | -$60Kn/m |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
NYMXF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2420-F | Q3'246-K | Q4'2320-F | Q3'236-K | Q2'236-K | Q1'236-K | Q4'2220-F | Q3'226-K |
|---|---|---|---|---|---|---|---|---|
| Return on Assets | N/A | N/A | N/A | N/A | N/A | -241.2%+169.6pp | N/A | N/A |
| Current Ratio | 0.09-0.1x | 0.09-0.2x | 0.16-0.5x | 0.25-1.0x | 0.07-1.8x | 0.19-0.2x | 0.69+0.1x | 1.24-0.6x |
| Liabilities-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3.06+1.6x |
| Asset Turnover | N/A | 0.000.0x | N/A | 0.000.0x | 0.000.0x | 0.000.0x | N/A | 0.000.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$6.8M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| NYMOX PHARM CORP NYMXF | FY2024 | N/A | N/A | N/A | $6.3M | — |
| ORGENESIS INC ORGS | FY2024 | $1.0M | N/A | N/A | N/A | — |
Where NYMOX PHARM CORP Ranks
Frequently Asked Questions
What is NYMOX PHARM CORP's free cash flow?
NYMOX PHARM CORP (NYMXF) recorded an outflow of $2.6M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NYMOX PHARM CORP's operating cash flow?
NYMOX PHARM CORP (NYMXF) recorded an outflow of $2.6M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are NYMOX PHARM CORP's total assets?
NYMOX PHARM CORP (NYMXF) had $654K in total assets as of fiscal year 2024, including both current and long-term assets.
What are NYMOX PHARM CORP's capital expenditures?
NYMOX PHARM CORP (NYMXF) reported no capital expenditure during fiscal year 2024.
What is NYMOX PHARM CORP's current ratio?
NYMOX PHARM CORP (NYMXF) had a current ratio of 0.09 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is NYMOX PHARM CORP's P/E ratio?
NYMOX PHARM CORP (NYMXF) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $6.3M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is NYMOX PHARM CORP's price-to-sales ratio?
NYMOX PHARM CORP (NYMXF) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $6.3M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is NYMOX PHARM CORP's debt-to-equity ratio negative or not reported?
NYMOX PHARM CORP (NYMXF) has negative shareholder equity of -$6.8M as of fiscal year 2024, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.